Tango Therapeutics, Inc. (TNGX)
| Market Cap | 3.86B +284.2% |
| Revenue (ttm) | 53.81M +121.5% |
| Net Income | -123.72M |
| EPS | -0.91 |
| Shares Out | 168.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,322,765 |
| Open | 22.02 |
| Previous Close | 22.20 |
| Day's Range | 21.81 - 23.51 |
| 52-Week Range | 7.12 - 34.39 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 47.09 (+105.72%) |
| Est. Earnings | Nov 10, 2026 |
About TNGX
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ... [Read more]
Financial Performance
In 2025, Tango Therapeutics's revenue was $62.38 million, an increase of 48.29% compared to the previous year's $42.07 million. Losses were -$101.59 million, -22.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price target is $47.09, which is an increase of 105.72% from the latest price.
News
Tango Therapeutics added to Analyst Focus List at JPMorgan
JPMorgan analyst Brian Cheng added Tango Therapeutics (TNGX) to the firms’ Analyst Focus List while keeping an Overweight rating on the shares with a $46 price target The firm views…
Tango Therapeutics falls -12.6%
Tango Therapeutics (TNGX) is down -12.6%, or -$3.51 to $24.42.
Tango Therapeutics price target raised to $55 from $40 at Stifel
Stifel analyst Laura Prendergast raised the firm’s price target on Tango Therapeutics (TNGX) to $55 from $40 and keeps a Buy rating on the shares. The updated vopimetostat/daraxonrasib data and…
Tango Therapeutics falls -17.5%
Tango Therapeutics (TNGX) is down -17.5%, or -$4.89 to $23.04.
Tango Therapeutics Transcript: Study result
Vopimetostat plus daraxonrasib produced an 82% confirmed ORR and 88% 9-month PFS in MTAP-deleted pancreatic cancer, with a tolerability profile described as improved versus daraxonrasib alone. A 484-patient first-line Phase III trial is planned for H1 2027.
Tango Therapeutics Press release: Study result
Tango Therapeutics issued a press release on October 23, 2026, disclosing material business information to investors.
Tango Therapeutics Slides: Study result
Tango Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Tango announces results from obngoing Phase 1/2 study of vopimetostat
Tango Therapeutics (TNGX) announced promising results from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination with ...
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib
Tango Therapeutics management to meet with Cantor
Breakfast Meeting to be held in Madrid on October 25 hosted by Cantor.
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET
Tango Therapeutics initiated with an Outperform at William Blair
William Blair analyst Alethia Young initiated coverage of Tango Therapeutics (TNGX) with an Outperform rating. Tango is a precision oncology company with an in-house CRISPR-based discovery engine that...
Tango Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Vopimetostat, a PRMT5 inhibitor, has shown unprecedented response rates in pancreatic cancer and is advancing toward regulatory approval, with a strong focus on combination therapies and expansion into lung cancer and glioblastoma. Mature data updates and regulatory strategy details are expected by year-end.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of ...
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to particip...
Tango Therapeutics price target raised to $68 from $66 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Tango Therapeutics (TNGX) to $68 from $66 and keeps a Buy rating on the shares following the Q2 report.
Tango Therapeutics price target raised to $35 from $32 at Guggenheim
Guggenheim raised the firm’s price target on Tango Therapeutics (TNGX) to $35 from $32 and keeps a Buy rating on the shares to account for Q2 updates and trends as…
Tango Therapeutics reports Q2 EPS (37c), consensus (32c)
“The second quarter marked a pivotal period for Tango, with milestones that validated our PRMT5 inhibitor pipeline and reflect the progress of our maturing organization. Notably, initial Phase 1/2 dat...
Tango Therapeutics Quarterly report: Q2 2026
Tango Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Tango Therapeutics Earnings release: Q2 2026
Tango Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Tango Therapeutics executive chairman Weber to step down
Tango Therapeutics (TNGX) announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits. “I am…
Tango Therapeutics Announces Executive Chair Transition
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cance...
Tango Therapeutics price target raised to $40 from $36 at Mizuho
Mizuho raised the firm’s price target on Tango Therapeutics (TNGX) to $40 from $36 and keeps an Outperform rating on the shares. The firm believes Revolution Medicines’ (RVMD) data for…
Tango Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of Tango Therapeutics (TNGX) with an Overweight rating and $46 price target The firm says Tango is “leading the way” in pancreatic ductal adenocarcinoma...
Tango Therapeutics price target raised to $46 from $42 at Canaccord
Canaccord raised the firm’s price target on Tango Therapeutics (TNGX) to $46 from $42 and keeps a Buy rating on the shares. The firm said they see additional upside for…